Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 470-479

  Whitley, Brandi R ^a   Beaulieu, Lea M ^a   Carter, Jennifer C ^a   Church, Frank C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Migration and invasion; PAI 1; PI3K Akt signaling system; Plasminogen activator system; SKOV 3 cells; Urokinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; RHO KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C; UROKINASE; WORTMANNIN;

ADENOVIRUS; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CELL MOVEMENT; CHROMONES; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MORPHOLINES; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 33846345880     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.048     Document Type: Article

References (48)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J. Clin. 56 2 (2006) 106-130
2. Brewer M.A., Johnson K., Follen M., Gershenson D., and Bast Jr. R. Prevention of ovarian cancer: intraepithelial neoplasia. Clin. Cancer Res. 9 1 (2003) 20-30
3. Stack M.S., Ellerbroek S.M., and Fishman D.A. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int. J. Oncol. 12 3 (1998) 569-576
4. Borgfeldt C., Hansson S.R., Gustavsson B., Masback A., and Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int. J. Cancer 92 4 (2001) 497-502
5. Konecny G., Untch M., Pihan A., Kimmig R., Gropp M., Stieber P., et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin. Cancer Res. 7 6 (2001) 1743-1749
6. Kuhn W., Pache L., Schmalfeldt B., Dettmar P., Schmitt M., Janicke F., et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55 3 Pt. 1 (1994) 401-409
7. van der Burg M., Henzen-Logmans S., Berns E., van Putten W., Klijn J., and Foekens J. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer 69 6 (1996) 475-479
8. Kuhn W., Schmalfeldt B., Reuning U., Pache L., Berger U., Ulm K., et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer 79 11-12 (1999) 1746-1751
9. Keely P.J., Westwick J.K., Whitehead I.P., Der C.J., and Parise L.V. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390 6660 (1997) 632-636
10. Tanno S., Mitsuuchi Y., Altomare D.A., Xiao G.H., and Testa J.R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 61 2 (2001) 589-593
11. Kotelevets L., Noe V., Bruyneel E., Myssiakine E., Chastre E., Mareel M., et al. Inhibition by platelet-activating factor of Src- and hepatocyte growth factor-dependent invasiveness of intestinal and kidney epithelial cells. Phosphatidylinositol 3′-kinase is a critical mediator of tumor invasion. J. Biol. Chem. 273 23 (1998) 14138-14145
12. Tanaka Y., Kobayashi H., Suzuki M., Kanayama N., and Terao T. Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J. Biol. Chem. 279 10 (2004) 8567-8576
13. Sliva D., Rizzo M.T., and English D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J. Biol. Chem. 277 5 (2002) 3150-3157
14. Mahabeleshwar G.H., and Kundu G.C. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3′-kinase activity in breast cancer cells. J. Biol. Chem. 278 8 (2003) 6209-6221
15. Kusch A., Tkachuk S., Haller H., Dietz R., Gulba D.C., Lipp M., et al. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J. Biol. Chem. 275 50 (2000) 39466-39473
16. Sturge J., Hamelin J., and Jones G.E. N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator. J. Cell. Sci. 115 Pt. 4 (2002) 699-711
17. Kiian I., Tkachuk N., Haller H., and Dumler I. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb. Haemostasis 89 5 (2003) 904-914
18. Chandrasekar N., Mohanam S., Gujrati M., Olivero W.C., Dinh D.H., and Rao J.S. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene 22 3 (2003) 392-400
19. Kietzmann T., Jungermann K., and Gorlach A. Regulation of the hypoxia-dependent plasminogen activator inhibitor 1 expression by MAP kinases. Thromb. Haemostasis 89 4 (2003) 666-673
20. Takahashi H., Uno S., Watanabe Y., Arakawa K., and Nakagawa S. Expression of nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA is inhibited by genistein and wortmannin. NeuroReport 11 5 (2000) 1111-1115
21. Ploplis V.A., Balsara R., Sandoval-Cooper M.J., Yin Z.J., Batten J., Modi N., et al. Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice. J. Biol. Chem. 279 7 (2004) 6143-6151
22. Dunn S.E., Torres J.V., Oh J.S., Cykert D.M., and Barrett J.C. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res. 61 4 (2001) 1367-1374
23. Venugopal J., Hanashiro K., Yang Z.Z., and Nagamine Y. Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes. Proc. Natl. Acad. Sci. U. S. A. 101 49 (2004) 17120-17125
24. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30 2 (2004) 193-204
25. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64 4 (1995) 280-285
26. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. U. S. A. 89 19 (1992) 9267-9271
27. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21 1 (1999) 99-102
28. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19 19 (2000) 2324-2330
29. Shen M.R., Lin A.C., Hsu Y.M., Chang T.J., Tang M.J., Alper S.L., et al. Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J. Biol. Chem. 279 38 (2004) 40017-40025
30. Whitley B.R., Palmieri D., Twerdi C.D., and Church F.C. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp. Cell Res. 296 2 (2004) 151-162
31. Abid M.R., Guo S., Minami T., Spokes K.C., Ueki K., Skurk C., et al. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24 2 (2004) 294-300
32. Degryse B., Sier C.F., Resnati M., Conese M., and Blasi F. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett. 505 2 (2001) 249-254
33. Hjortland G.O., Bjornland K., Pettersen S., Garman-Vik S.S., Emilsen E., Nesland J.M., et al. Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clin. Exp. Metastasis 20 4 (2003) 301-309
34. Kjoller L., Kanse S.M., Kirkegaard T., Rodenburg K.W., Ronne E., Goodman S.L., et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232 2 (1997) 420-429
35. Praus M., Collen D., and Gerard R.D. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int. J. Cancer 102 6 (2002) 584-591
36. Ellerbroek S.M., Halbleib J.M., Benavidez M., Warmka J.K., Wattenberg E.V., Stack M.S., et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 61 5 (2001) 1855-1861
37. Imai Y., and Clemmons D.R. Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyriboncleic acid synthesis by insulin-like growth factor-I. Endocrinology 140 9 (1999) 4228-4235
38. Reiske H.R., Kao S.C., Cary L.A., Guan J.L., Lai J.F., and Chen H.C. Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J. Biol. Chem. 274 18 (1999) 12361-12366
39. Kobayashi H., Suzuki M., Kanayama N., and Terao T. Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells. J. Biol. Chem. 279 8 (2004) 6371-6379
40. Das R., Mahabeleshwar G.H., and Kundu G.C. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. 278 31 (2003) 28593-28606
41. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63 1 (2003) 196-206
42. Sumigama S., Ito T., Kajiyama H., Shibata K., Tamakoshi K., Kikkawa F., et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha. Oncogene (2004)
43. Hirano S., Ito N., Takahashi S., and Tamaya T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur. J. Gynaecol. Oncol. 25 2 (2004) 187-191
44. Lukanova A., Lundin E., Toniolo P., Micheli A., Akhmedkhanov A., Rinaldi S., et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int. J. Cancer 101 6 (2002) 549-554
45. Boyd D.B. Insulin and cancer. Integr. Cancer Ther. 2 4 (2003) 315-329
46. Tanaka Y., Kobayashi H., Suzuki M., Hirashima Y., Kanayama N., and Terao T. Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis. Int. J. Cancer 109 3 (2004) 336-347
47. Andreasen P.A., Egelund R., and Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57 (2000) 25-40
48. Stefansson S., and Lawrence D.A. Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci. STKE 2003 189 (2003) pe24